Chemistry: analytical and immunological testing – Biospecific ligand binding assay
Patent
1995-05-22
1999-03-16
Tsang, Cecilia J.
Chemistry: analytical and immunological testing
Biospecific ligand binding assay
435 71, 514 2, G01N 33566, G01N 3353
Patent
active
058829440
ABSTRACT:
A method for screening G protein coupled receptors is provided in which G protein coupled receptors that are constitutively active are determined, such as by measuring receptor phosphorylation agonist independent signalling. When a G protein coupled receptor is found to be regulated by constitutive activity, then assay systems may be set up to classify test compounds as agonists, neutral antagonists, or negative antagonists with respect to G protein coupled receptor signalling and phosphorylation. Such determinations and screening are useful for selecting new pharmaceuticals potentially useful in treating disease states mediated by G protein coupled receptors, with applications including treatments in conjunction with narcotic analgesia.
REFERENCES:
patent: 5061715 (1991-10-01), Sunkara et al.
Biedler et al., "Morphology and Growth, Tumorigenicity, and Cytogenetics of Human Neuroblastoma Cells in Continuous Culture," Cancer Res., 33, pp. 2643-2652 (1973).
Costa et al., "Drug Efficacy at Guanine Nucleotide-Binding Regulatory Protein-Linked Receptors: Thermodynamics Interpretation of Negative Antagonism . . . ," Molec. Pharmacol., 41, pp. 549-560 (1992).
Frey et al., "A .mu.-Opioid Receptor in 7315c Tumor Tissue Mediates Inhibition of Immunoreactive Prolactin Release and Adenylate Cyclase Activity," Endocrin., 115, pp. 1797-1804 (1984).
Kogan et al., "Elevated Basal Firing Rates and Enhanced Responses to 8-Bromo-cAMP in Locus coeruleus Neurons in Brain Slices from Opiate Dependent Rats," Eur. J. Pharmacol., 211, pp. 47-53 (1992).
Nestler, "Molecular Mechanisms of Drug Addiction," J. Neurosci. 12:7, pp. 2439-2450 (1992).
Rasmussen et al., "Opiate Withdrawal and the Locus coeruleus: Behavioral, Elactrophysiological, and Biochemical Correlates," J. Neurosci., 10, pp. 2308-2317 (1990).
Sibinga et al., "Opioid Peptides and Opioid Receptors in Cells of the Immune System," Ann. Rev. Immunol., 6, pp. 219-249 (1988).
Yu et al., "A Human Neuroblastoma Cell Line Expresses .mu. and .delta. Opioid Receptor Sites," J. Biol. Chem., 261, pp. 1065-1070 (1986).
Yu et al., "Efficacy and Tolerance of Narcotic Analgesics at the .mu. Opioid Receptor in Differentiated Human Neuroblastoma Cells," J. Pharmacol. Exp. Ther., 245, pp. 350-355 (1988).
Yu et al., "Differentiation of Human Neuroblastoma Cells: Marked Potentiation of Prostaglandin E-Stimulated Accumulation of cAMP by Retinoic Acid," J. Neurochem., 51, pp. 1892-1899 (1988).
Yu et al., "Regulation of Cyclic AMP by the .mu.-Opioid Receptor in Human Neuroblastoma SH-SY5Y Cells," J. Neurochem., 55:4, pp. 1390-1396 (1990).
Schutz et al., "Reverse Intrinsic Activity of Antagonists of G Protein-Coupled Receptors," TiPS, 13 (Oct. 1993), pp. 376-379.
Chen et al., "Moleculare Cloning and Functional Expression of a .mu.-Opioid Receptor from Rat Brain," Molecular Pharmacology, 44, pp. 8-12 (1993).
Wang et al., "Constitutive .mu. Opioid Receptor Activation as a Regulatory Mechanism Underlying Narcotic Tolerance and Dependence," Life Sciences, 54:20, pp. 339-350 (1994).
Smith et al., "Problems and Approaches in Studying Membrane Opioid Receptors," Molecular Approaches to Drug Abuse Research vol. I, edited by Lee et al., U.S. Dept. of Health & Human Services, pp. 69-84 (1991). Receptors in Rat Brain," J. Pharmacol. & Exp. Ther., 248:1, pp. 73-80 (1989).
Abdelhamid et al., "Characteristics of .mu. and .delta. Opioid Binding Sites in Striatal Slices of Morphine-Tolerant and -Dependent Mice," Eur. J. Pharmacol., 198, pp. 157-163 (1991).
Sharma et al., "Dual Regulation of Adenylate Cyclase Accounts for Narcotic Dependence and Tolerance," Proc. Antl. Acad. Sci. USA, 72:8, pp. 3092-3096 (1975).
Sadee et al., "Constitutive Activation of the .mu.-Opioid Receptor: A Novel Paradigm of Receptor Regulation in Narcotic Analgesia, Tolerance, and Dependence," Analgesia, 1:1, pp. 11-14 (1994).
Lameh et al., Abstract of "Agonist Induced Conversion of the Hm1 Muscarinic Cholinergic Receptor to a Constitutively Active State: A Novel Papadigm of Receptor Regulation," p. 47 of the program for Subtypes of Muscarinic Receptors: The Sixth International Symposium, Sponsered by Boston University School of Medicine and Johann Wolfgang-Goethe University, held in Fort Lauderdale, Florida, Nov. 9-12, 1994.
Baker, Mitzi, "New Hypothesis on How Narcotics Produce Tolerance, Dependency," Synapse (newspaper of the Universiy of California, San Francisco), 39:15 (Jan. 12, 1995), pp. 1 and 5.
Hogger et al., "Activating and Inactivating Mutations in N- and C- terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors," J. Biol. Chem., 270:13, (1995), pp. 7405-7410.
Wang et al., "Agonist Induced Constitutive Activation of the .mu. Opioid Receptor by Phosphorylation," Regulatory Peptides, 54:1, (1994), pp. 323-324.
Wang et al. Constitutive m opioid receptor activation . . . Life Sciences, 54: 339-350, Apr. 10, 1994.
Costa et al. Antagonists with negative intrinsic activity at delta opiod receptors coupled to GTP-binding proteins. Proc. Niatl. Acad. Sci., USA, 86: 7321-7325, Oct. 1989.
Sharma S.K. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc. Natl. Acad. Sci. USA, 72 (8): 3092-3096, Aug. 1975.
Borin Michael
The Regents of the University of California
Tsang Cecilia J.
LandOfFree
Methods for G protein coupled receptor activity screening does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for G protein coupled receptor activity screening, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for G protein coupled receptor activity screening will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-816877